期刊文献+

[^(18)F]标记表皮生长因子受体抑制剂显像剂全自动合成方法

One-Pot Automatic Production of ^(18)F-labelled Tyrosine Kinase Inhibitor of Epidermal Growth Factor Receptor
原文传递
导出
摘要 目的:[18F]标记表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)正电子显像剂在指导肿瘤分子靶向治疗中具有非常重要的作用。本文目的是找到一种全自动、适合日常使用的[18F]标记EGFR-TKI正电子显像剂的全自动合成方法。方法:采用一步法合成[18F]EGFR-TKI PET显像剂。首先合成4-[18F]氟苯胺基,然后合成4-[18F]氟苯胺基-6,7-二甲氧基喹唑啉。结果:整个合成过程大约60分钟,产率25%-35%(未校正),放化纯度>95%。结论:本文建立了一种适合临床日常应用的[18F]EGFR-TKI PET显像剂的全自动合成方法。该方法对于进一步开发新型[18F]标记的表皮生长因子受体抑制剂PET显像具有重要价值。 ABSTRACT Objective: [^18F]-labelled tyrosine kinase inhibitor of epidermal growth factor receptor is often used for guidance on treatment of EGFR overexpressed cancer. Our objective is to develop a fully automatic method of routine production of [^18F]-labelled EGFR-TKI. Methods: A new one-pot method is used. The first step is synthesis of 4- [^18F] fluoroaniline, then 4- [^18F] fluorine based 6, 7- dimethoxy-anilinoquinazoline. Results: The total radiosynthesis time is 70 minutes after EOB. The radiochemical yield is 25%-35% (decay uncorrected), and the radiochemical purity is more than 95%. Conclusion: The one-pot automatic synthesis of [^18F] labelled tyrosine kinase inhibitor of epidermal growth factor receptor is promising for routine use. Key words: [^18F]; EGFR-TKI; PET; Automatic synthesis
出处 《现代生物医学进展》 CAS 2012年第29期5635-5637,5642,共4页 Progress in Modern Biomedicine
基金 国家自然基金委项目(重点项目)(81130028) 黑龙江省科技攻关项目(重大项目)(GA12C302) 科技部国际合作项目(2009DFB30040) 中国博士后科学基金(2012M510095)
关键词 [18F] 表皮生长因子受体酪氨酸激酶抑制剂 PET 全自动合成 [^18F] EGFR-TKI PET Automatic synthesis
  • 相关文献

参考文献15

  • 1Arteaga CL. ErbB-targeted therapeutic approaches in human cancer [J]. Exp Cell Res, 2003, 284(1):122-130.
  • 2Slobbc Paul, Pont Alex J, Windhorst Albert D, et al. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET [J]. Drug Discov- ery Today, In Press, Available online, 2 July 2012.
  • 3Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase:a promising therapeutic target in solid tumors [J]. Semin Oncol, 2003, 30:3.
  • 4Jeffrey Jie-Lou Liao. Molecular Recognition of Protein Kinase Binding Pockets lbr Design of Potent and Selective Kinase Inhibitors [J]. J Med Chem, 2007, 50 (3): 409-424.
  • 5Arteaga CL. ErbB-targeted therapeutic approaches in human cancer [J]. Exp Cell Res, 2003, 284:122-130.
  • 6Bridges A J, Zhou H, Cody DR, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4- (3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J]. J Med Chem, 1996, 39( 1 ):267-276.
  • 7Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects [J]. Curr Drug Metab, 2009, 10(5):470-481.
  • 8Peter Johnstrtim, Anna Fredriksson, Jan-Olov Thorell, et al. Synthesis of [Methoxy-1 IC]PD153035, a selective EGF Receptor Tyrosine Kinase Inhibitor [J]. J. Labelled Compd. Radiopharm, 1998, 41, 623-629.
  • 9Fredriksson A, Johnstriim P, Thorell JO, et al. In vivo cvaluation of the biodistribution of 1 IC-labeled PD153035 in rats without and with neuroblastoma implants [J]. Life Sci, 1999, 65:165-174.
  • 10Liu N, Li M, Li X, et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans [J]. J Nucl Med, 2009, 150:2303-2308.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部